Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

doi:10.1053/j.seminoncol.2017.02.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Seminars in oncology - 1 Feb 2017

Boisdron-Celle Michele, Capitain Olivier, Faroux Roger, Borg Christophe, Metges Jean Philippe, Galais Marie Pierre, Kaassis Mehdi, Bennouna Jaafar, Bouhier-Leporrier Karine, Francois Eric, Baumgaertner Isabelle, Guerin-Meyer Véronique, Cojocarasu Oana, Roemer-Becuwe Celia, Stampfli Claire, Rosenfeld Ludovic, Lecompte Thierry, Berger Virginie, Morel Alain, Gamelin Erick

Abstract excerpt

5-Fluorouracil (5-FU)-based treatments can lead to early-onset severe (4%-5%) even fatal (0.3%) toxicities in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This multicenter prospective cohort study aimed to assess the clinical benefit of pretherapeutic screening for DPD deficiency using a multiparametric approach. Two parallel cohorts of patients treated with 5-FU-based chemotherapy for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antimetabolites, Antineoplastic

Share to Cohort Studies

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Genotype

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed

Identifiers

PMID: 28395758
DOI: 10.1053/j.seminoncol.2017.02.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.PMID 28395758Read ↗

Evaluation of chemotherapy toxicities in patients receiving treatment for gastrointestinal cancers and therapeutic monitoring of 5-fluorouracil as a clinical support tool.Semantic proximity Read ↗

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?Semantic proximity Read ↗

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.Semantic proximity Read ↗

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity Read ↗

A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.Semantic proximity Read ↗

Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?Semantic proximity Read ↗

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Semantic proximity Read ↗

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.Semantic proximity Read ↗

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.Semantic proximity Read ↗

[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.